vs
Side-by-side financial comparison of American Healthcare REIT, Inc. (AHR) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $564.0M, roughly 1.1× American Healthcare REIT, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs 1.9%, a 32.5% gap on every dollar of revenue. On growth, American Healthcare REIT, Inc. posted the faster year-over-year revenue change (13.5% vs 4.8%). Over the past eight quarters, American Healthcare REIT, Inc.'s revenue compounded faster (11.7% CAGR vs 4.6%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
AHR vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $564.0M | $622.0M |
| Net Profit | $10.8M | $214.2M |
| Gross Margin | 14.8% | — |
| Operating Margin | 19.8% | 62.4% |
| Net Margin | 1.9% | 34.4% |
| Revenue YoY | 13.5% | 4.8% |
| Net Profit YoY | 133.9% | 2.9% |
| EPS (diluted) | $0.07 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $564.0M | $622.0M | ||
| Q3 25 | $532.1M | $609.3M | ||
| Q2 25 | $501.3M | $578.7M | ||
| Q1 25 | $497.2M | $568.2M | ||
| Q4 24 | $496.8M | $593.6M | ||
| Q3 24 | $476.8M | $564.7M | ||
| Q2 24 | $458.0M | $537.3M | ||
| Q1 24 | $452.1M | $568.0M |
| Q4 25 | $10.8M | $214.2M | ||
| Q3 25 | $55.9M | $288.2M | ||
| Q2 25 | $9.9M | $30.2M | ||
| Q1 25 | $-6.8M | $238.3M | ||
| Q4 24 | $-31.8M | $208.2M | ||
| Q3 24 | $-4.1M | $544.0M | ||
| Q2 24 | $2.0M | $102.0M | ||
| Q1 24 | $-3.9M | $4.8M |
| Q4 25 | 14.8% | — | ||
| Q3 25 | 14.6% | — | ||
| Q2 25 | 15.0% | — | ||
| Q1 25 | 13.0% | — | ||
| Q4 24 | 13.3% | — | ||
| Q3 24 | 12.5% | — | ||
| Q2 24 | 12.1% | — | ||
| Q1 24 | 10.7% | — |
| Q4 25 | 19.8% | 62.4% | ||
| Q3 25 | 19.9% | 70.1% | ||
| Q2 25 | 20.6% | 36.3% | ||
| Q1 25 | 19.0% | 94.0% | ||
| Q4 24 | 20.0% | 60.9% | ||
| Q3 24 | 19.6% | — | ||
| Q2 24 | 19.4% | 50.2% | ||
| Q1 24 | 18.2% | -13.0% |
| Q4 25 | 1.9% | 34.4% | ||
| Q3 25 | 10.5% | 47.3% | ||
| Q2 25 | 2.0% | 5.2% | ||
| Q1 25 | -1.4% | 41.9% | ||
| Q4 24 | -6.4% | 35.1% | ||
| Q3 24 | -0.9% | 96.3% | ||
| Q2 24 | 0.4% | 19.0% | ||
| Q1 24 | -0.9% | 0.8% |
| Q4 25 | $0.07 | $0.49 | ||
| Q3 25 | $0.33 | $0.67 | ||
| Q2 25 | $0.06 | $0.07 | ||
| Q1 25 | $-0.04 | $0.55 | ||
| Q4 24 | $-0.23 | $0.46 | ||
| Q3 24 | $-0.03 | $1.21 | ||
| Q2 24 | $0.01 | $0.23 | ||
| Q1 24 | $-0.04 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $114.8M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $3.3B | $9.7B |
| Total Assets | $5.4B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $114.8M | $618.7M | ||
| Q3 25 | $147.4M | $938.9M | ||
| Q2 25 | $133.5M | $631.9M | ||
| Q1 25 | $86.1M | $1.1B | ||
| Q4 24 | $76.7M | $929.0M | ||
| Q3 24 | $67.8M | $950.1M | ||
| Q2 24 | $52.1M | $1.8B | ||
| Q1 24 | $77.0M | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $3.3B | $9.7B | ||
| Q3 25 | $2.7B | $9.6B | ||
| Q2 25 | $2.4B | $9.5B | ||
| Q1 25 | $2.3B | $9.8B | ||
| Q4 24 | $2.3B | $10.3B | ||
| Q3 24 | $2.2B | $10.3B | ||
| Q2 24 | $1.9B | $9.8B | ||
| Q1 24 | $2.0B | $9.9B |
| Q4 25 | $5.4B | $19.6B | ||
| Q3 25 | $4.8B | $19.3B | ||
| Q2 25 | $4.5B | $18.3B | ||
| Q1 25 | $4.5B | $17.6B | ||
| Q4 24 | $4.5B | $18.2B | ||
| Q3 24 | $4.7B | $18.0B | ||
| Q2 24 | $4.6B | $17.7B | ||
| Q1 24 | $4.7B | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $55.2M | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 5.12× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $55.2M | $827.1M | ||
| Q3 25 | $107.2M | $702.6M | ||
| Q2 25 | $71.5M | $364.0M | ||
| Q1 25 | $60.6M | $596.1M | ||
| Q4 24 | $59.5M | $742.5M | ||
| Q3 24 | $63.1M | $703.6M | ||
| Q2 24 | $59.4M | $658.2M | ||
| Q1 24 | $-6.0M | $664.6M |
| Q4 25 | 5.12× | 3.86× | ||
| Q3 25 | 1.92× | 2.44× | ||
| Q2 25 | 7.21× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 30.02× | 6.45× | ||
| Q1 24 | — | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AHR
| Integrated Senior Health Campuses | $467.0M | 83% |
| SHOP | $97.0M | 17% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
